STOCK TITAN

[SCHEDULE 13G] Ascendis Pharma A/S Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Ascendis Pharma A/S ownership disclosure: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,162,042 ADRs, equal to 9.9% of the class as reported 03/31/2026. The filing lists sole voting power for 5,884,715 shares and sole dispositive power for 6,162,042 shares.

Positive

  • None.

Negative

  • None.





04351P101

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:05/07/2026